Pegozafermin Drug Asset Due Diligence Report 2026

This Pegozafermin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pegozafermin can convert its Growth factors profile and FGF21R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pegozafermin (query alias: pegozafermin)
Modality / target	Growth factors; FGF21R; FGF21R agonists
Highest global status	Phase 3
Originator	89bio, Inc.
Active developers	Roche China Holding Ltd., 89bio, Inc., Incog Biopharma

The MCP disease footprint includes Fibrosis, Liver, Compensated cirrhosis, Fibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06318169	Phase 3	Recruiting	1350	Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52
NCT06419374	Phase 3	Recruiting	762	Proportion of Participants Achieving Fibrosis Regression
NCT05852431	Phase 3	Completed	369	Percent change from baseline in fasting TG

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase 2; n=222; evaluation: not stated. Reported fields: Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis: Treatment Difference = 34.65(95% CI, 10.04 - 59.26), P-Value = <0.0001; Treatment Difference = 20.89(95% CI, 9.05 - 32.72), P-Value = 0.0009; Treatment Difference = 23.61(95% CI, 10.04 - 37.18), P-Value = 0.0005; Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis: Treatment Difference = 34.65(95% CI, 10.04 - 59.26), P-Value = <0.0001; Treatment Difference = 20.89(95% CI, 9.05 - 32.72), P-Value = 0.0009; Treatment Difference = 23.61(95% CI, 10.04 - 37.18), P-Value = 0.0005; Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis: Treatment Difference = 34.65(95% CI, 10.04 - 59.26), P-Value = <0.0001; Treatment Difference = 20.89(95% CI, 9.05 - 32.72), P-Value = 0.0009; Treatment Difference = 23.61(95% CI, 10.04 - 37.18), P-Value = 0.0005

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

Phase 2; n=86; evaluation: not stated. Reported fields: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)(Median) = -11.85 percent change from Baseline (Inter-Quartile Range, -23.22 to 7.88); Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)(Median): Median Percent Change Difference = -43.73(95% CI, -57.08 to -30.31), P-Value = <0.001; Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)(Median): Median Percent Change Difference = -43.73(95% CI, -57.08 to -30.31), P-Value = <0.001

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100 Administered Subcutaneously in Subjects With Nonalcoholic Steatohepatitis (NASH) or With Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Phase 1/2; n=101; evaluation: not stated. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pegozafermin addresses Fibrosis, Liver, Compensated cirrhosis, Fibrosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Growth factors—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-09-18	Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH	Phase 3	US$3,500.0M stated total
2018-10-25	89Bio to purchase Teva's NASH therapeutics	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO